- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04101578
Clinical Prognosis and Progression of Myasthenia Gravis Patients
August 19, 2021 updated by: Da, Yuwei, M.D.
Prospective Observational Trial to Evaluate Clinical Prognosis and the Risk Factors for Progression for Myasthenia Gravis Patients
This study collects the clinical data of myasthenia gravis (MG) patients, assesses outcomes and adverse effects of different treatment regimens, and searches for risk factors of conversion to generalized MG.
Study Overview
Status
Recruiting
Conditions
Detailed Description
This is a multicenter, observational cohort trial in the real-world clinical setting recruiting MG patients from Neurology Departments of 6 hospitals in different regions of China.
Clinical manifestations, laboratory test results, chest imaging and history of thymectomy are recorded.
Patients will be classified by clinical manifestation as well as antibody status, and treatment regimens are determined according to the physician's judgment and preferences of the patients.
Patients are followed up prospectively on regular to assess the outcomes of treatments and monitor any side effects.
Peripheral blood samples are collected annually.
Patients' clinical records are uploaded to an online database.
The investigators plan to recruit a final sample of 2000 patients for analysis.
Study Type
Observational
Enrollment (Anticipated)
2000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100053
- Recruiting
- Xuan Wu Hospital, Capital Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years and older (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with Myasthenia Gravis
Description
Inclusion Criteria:
- Age >14.
Clinical Diagnosis of MG with supporting evidence:
- unequivocal clinical response to pyridostigmine
- positive antibody testing
- decrement >10% in repetitive nerve stimulations study (RNS) .
- Willingness to sample collection, imaging study and other disease-related examinations and assessments.
- Patients with informed consent.
Exclusion Criteria:
- History of chronic degenerative, psychiatric, or neurologic disorder other than MG that can produce weakness or fatigue.
- Age ≤14 years.
- Severe anxiety, depression or schizophrenia.
- Cognitive impairment or mini-mental state examination (MMSE) score ≤24.
- Severe systemic illness with life-expectancy less than 4 years.
- Unwillingness to consent for collection of biological samples.
- Inability to provide informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Ocular MG
Patients with autoimmune MG whose symptoms restricted to extraocular muscles
|
Treatment regimens are determined according to the physician's judgment and preferences of the patients.
Other Names:
|
Generalized MG
Patients not only suffer from extraocular muscles weakness but also from limb weakness, bulbar symptoms, or even respiratory failure
|
Treatment regimens are determined according to the physician's judgment and preferences of the patients.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Conversion rates from ocular to generalized MG at the last visit and risk factors.
Time Frame: Baseline, 48 months
|
Ocular MG patients are followed up to determine the ratio of conversion to generalized disease at the end of follow-up.
The clinical records will be retrospectively analyzed to search for risk factors of progressing.
|
Baseline, 48 months
|
Change in Quantitative Myasthenia Gravis (QMG) Scores from Baseline to 48 months.
Time Frame: Baseline, 12 months, 24 months, 36 months, 48 months
|
The QMG is a 13-item scale which measures ocular, bulbar, limb function and respiratory function.
The total score ranges from 0 (no myasthenic findings) to 39 (maximal myasthenic deficits) obtained by summing the responses to each individual item (None=0, Mild=1, Moderate=2, Severe=3).
|
Baseline, 12 months, 24 months, 36 months, 48 months
|
Change in MG-specific Activities of Daily Living scale (MG-ADL).
Time Frame: Baseline,3months, 6 months, 9 months, 12 months, 18 months, 24 months, 30months, 36 months, 42 months, 48 months
|
The MG-ADL is an 8-item scale to assess symptoms of myasthenia gravis patients obtained by summing the responses to each individual item (Grades: 0,1,2,3).
The score ranges from 0 to 24.
|
Baseline,3months, 6 months, 9 months, 12 months, 18 months, 24 months, 30months, 36 months, 42 months, 48 months
|
The proportion of patients reaching minimal manifestations (MM) or better.
Time Frame: 48 months
|
Clinical statuses of patients are assessed and categorized according to Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS).
MM or better includes Minimal Manifestation (MM), Pharmacologic Remission (PR) or Complete Remission (CR).
|
48 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Patients with Treatment-related Adverse Experiences.
Time Frame: 3 months, 6 months, 12 months, 24 months, 36 months, 48 months
|
Treatment-Related Adverse Events (AEs) are evaluated in patients of different regimens.
|
3 months, 6 months, 12 months, 24 months, 36 months, 48 months
|
Changes in titers of MG antibodies.
Time Frame: Baseline, 12 months, 24 months, 36 months, 48 months
|
MG antibodies are detected at enrollment and the titers of antibodies will be monitored annually.
|
Baseline, 12 months, 24 months, 36 months, 48 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: yuwei Da, M.D., Xuan Wu Hospital, Capital Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
February 8, 2017
Primary Completion (ANTICIPATED)
June 1, 2023
Study Completion (ANTICIPATED)
December 31, 2024
Study Registration Dates
First Submitted
September 16, 2019
First Submitted That Met QC Criteria
September 23, 2019
First Posted (ACTUAL)
September 24, 2019
Study Record Updates
Last Update Posted (ACTUAL)
August 23, 2021
Last Update Submitted That Met QC Criteria
August 19, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Neoplasms
- Autoimmune Diseases of the Nervous System
- Autoimmune Diseases
- Neoplasms by Site
- Neurologic Manifestations
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Neuromuscular Manifestations
- Nervous System Neoplasms
- Paraneoplastic Syndromes, Nervous System
- Paraneoplastic Syndromes
- Neuromuscular Junction Diseases
- Muscle Weakness
- Myasthenia Gravis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Dermatologic Agents
- Anti-Bacterial Agents
- Anticonvulsants
- Antibiotics, Antineoplastic
- Antifungal Agents
- Reproductive Control Agents
- Antitubercular Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Antibiotics, Antitubercular
- Calcineurin Inhibitors
- Cholinesterase Inhibitors
- Methylprednisolone
- Cyclophosphamide
- Immunoglobulins
- Immunoglobulins, Intravenous
- Prednisone
- Methotrexate
- Azathioprine
- Tacrolimus
- gamma-Globulins
- Rho(D) Immune Globulin
- Mycophenolic Acid
- Bromides
- Cyclosporine
- Cyclosporins
- Immunosuppressive Agents
- Pyridostigmine Bromide
Other Study ID Numbers
- 2017YFC0907705
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myasthenia Gravis
-
Assiut UniversityRecruitingNervous System Diseases | Autoimmune Diseases of the Nervous System | Thymoma | Myasthenia Gravis | Neuromuscular Junction Diseases | Myasthenia Gravis, Generalized | Myasthenia Gravis Crisis | Myasthenia Gravis, Ocular | Myasthenia Gravis, Juvenile Form | Thymus Hyperplasia | Myasthenia Gravis With Exacerbation... and other conditionsEgypt
-
Universiti Putra MalaysiaEnrolling by invitationExperimental MyastheniaChina
-
Universiti Putra MalaysiaCompletedExperimental MyastheniaChina
-
Alexion Pharmaceuticals, Inc.CompletedMyasthenia Gravis | Myasthenia Gravis, Generalized | Myasthenia Gravis, Juvenile FormUnited States, Japan, Netherlands
-
COUR Pharmaceutical Development Company, Inc.Not yet recruitingMyasthenia Gravis | Generalized Myasthenia | AChR Myasthenia Gravis | MuSK MGUnited States
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
University of Missouri-ColumbiaUniversity of Kansas Medical CenterRecruitingGeneralized Myasthenia GravisUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
Alexion Pharmaceuticals, Inc.RecruitingGeneralized Myasthenia GravisChina, United States, Spain, United Kingdom, Korea, Republic of, Italy, Germany, Japan, Brazil, France, Netherlands, Taiwan, Turkey, Israel, Poland, Austria, Denmark, Portugal, Canada, Serbia, Argentina, Switzerland
-
Immunovant Sciences GmbHRecruitingGeneralized Myasthenia GravisUnited States, Poland, Romania, Italy, Georgia, Korea, Republic of, Canada, Japan, Hungary, Spain, Serbia, Germany
Clinical Trials on Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)
-
Institute for Clinical and Experimental MedicineRecruiting
-
University of CambridgeUniversity of Oxford; Stanley Medical Research Institute; McPin FoundationCompletedSchizophrenia | Psychosis | Auto Immune DisordersUnited Kingdom
-
Hansa Biopharma ABRecruitingKidney Transplantation in Highly Sensitized PatientsUnited States
-
Assiut UniversityCompletedGuillain-Barre SyndromeEgypt
-
Emory UniversityGeorgia Institute of TechnologyTerminatedChronic Inflammatory Demyelinating PolyneuropathyUnited States
-
Assiut UniversityUnknownGuillain-Barre Syndrome
-
University of Colorado, DenverVeloxis PharmaceuticalsTerminatedKidney Transplant RejectionUnited States
-
Anhui Provincial HospitalNot yet recruitingHigh Titers of Anti-HLA Antibody (MFI ≥5000)China
-
Brigham and Women's HospitalAlexion PharmaceuticalsTerminatedAntibody-mediated Rejection | Humoral RejectionUnited States
-
Peking University First HospitalTerminatedKidney Diseases | Glomerulonephritis, IGA | Acute Renal Insufficiency | Rapidly Progressive GlomerulonephritisChina